Pfizer's 7% Yield: A Gift or a Warning for Retirees?

Pfizer (NYSE:PFE) shares trade at $24.37, offering a dividend yield of 7.27%, one of the highest among large-cap healthcare stocks. However, this attractive yield comes amid a sharp decline in COVID-19 product revenues, raising skepticism among investors.

Recommendation Change

No specific analyst recommendation change is mentioned in the article. Instead, the article debates whether the high yield presents a buying opportunity or a warning of potential dividend cuts.

Analyst's Rationale

The article poses the question: Is the 7.27% yield a gift or a warning? The analysis is based on:

• Comirnaty revenue decline of 59% in Q1 2026.
• Paxlovid revenue decline of 63% in the same period.
• The company's continued dividend payments despite these declines.

Context

While COVID revenues have eroded, Pfizer maintains a broad portfolio of other drugs. However, the key question is whether current dividends are sustainable given the revenue drop from key products.

What We Conclude

The high yield may be attractive for retirees seeking income, but it carries risks if revenue declines persist without new product offsets. Investors should monitor dividend sustainability and diversify their portfolios.